[Intra-arterial treatment of arterial obliterative disease (author's transl)].
D000255:Adenosine Triphosphate / Q000008:administration & dosage* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000378:metabolism; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000188:drug therapy; D005260:Female; D005734:Gangrene / Q000188:drug therapy; D006801:Humans; D007270:Injections, Intra-Articular; D007773:Lactates / Q000378:metabolism; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D011773:Pyruvates / Q000378:metabolism; D011928:Raynaud Disease / Q000188:drug therapy; D013919:Thromboangiitis Obliterans / Q000188:drug therapy
D007773:Lactates; D011773:Pyruvates; D000255:Adenosine Triphosphate
Zur intraateriellen Behandlung der arteriellen Verschlusskrankheit